What Researchers Did
Canadian researchers from Ottawa reported a case of an elderly woman with cold agglutinin disease who developed severe nasal ischemia, treated with a novel combination of aspirin, low molecular weight heparin, nitroglycerin ointment, and HBOT.
What They Found
The nasal ischemia resolved completely with no residual tissue loss or sequelae. This was the first reported case using either nitroglycerin ointment or HBOT successfully for cold agglutinin disease-induced cutaneous ischemia in the head and neck.
What This Means for Canadian Patients
This Canadian case demonstrates that HBOT can salvage tissue in rare ischemic emergencies that have no established treatment. Canadian otolaryngologists and hematologists managing cold agglutinin disease complications now have a published Canadian protocol to reference.
Canadian Relevance
This is a Canadian study from Ottawa; it demonstrates HBOT use in a Canadian hospital setting.
Study Limitations
A single case report cannot establish treatment efficacy; the multi-drug protocol makes it impossible to attribute benefit specifically to HBOT.